Hints and tips:
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...I think a lot of people were anticipating a V-shaped recovery . . . People are now waking up the realisation that volatility is going to be normal going forward.”...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Barney Graham, one of the US government scientists who helped develop that vaccine, told the FT earlier this year the patent gave the government “leverage” over Moderna....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Letter in response to this editorial: Help companies do more to protect themselves from takeover / From Graham Mather, London, UK...
...“I think Akzo has bigger challenges ahead than PPG to justify its current share price,” said Graham Copley of SSR, the investment research firm....
...(Masslive.com) Campaign commentary Thank Reagan and Bill Clinton for Trump’s dog whistle ways (Sally Kohn, Time) The media v Trump (Ezra Klein, Vox) Trump may cost the GOP a generation of voters (Michael...
...Social media now sends almost as much traffic to news sites as Google — 36 per cent v 41 per cent. Traffic diversion on this scale poses a dilemma for publishers....
...The fund bought into a host of US stocks, including Pfizer, the pharmaceutical company, and General Electric, the multinational conglomerate....
...Graham Smith, editor of the regional paper, the East Kent Mercury, says many felt betrayed. “[Pfizer] were really powerful. They had roads built to serve them....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...the UK’s Reckitt Benckiser has been so high that its price – initially estimated by analysts at $8bn-$10bn, has escalated towards $14bn, making it: “more eye-watering than mouth-watering,” according to Graham...
...That produced dubious results but, undaunted, Pfizer has suggested a $100bn merger to AstraZeneca of the UK....
...He reportedly outbid three kings for it, including Britain’s King George V – today it remains the only rare stamp not in the Queen’s collection....
...Investment strategy: A value investor and a disciple of Ben Graham, Mr Watsa invests via his insurance company Fairfax Financial Holdings....
...“We decided to bring the jobs to where the people were and it has worked really well,” said Graham Jackson, North of England business manager of Wood Group PSN....
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Drug companies look like what Benjamin Graham called “cigar butt” stocks – thrown away, but still with a puff in them. As for UK politicians and commentators, less hand-wringing is called for....
...You’re spraying Golden Grahams! Say the mantra your counsellor gave you if you’re getting flashbacks. We’ll try to forget JJB. Everyone else has. jonathan.guthrie@ft.com...
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...“These indicators don’t just follow a V-shape, they will falter. The question is to what extent we’ve now double-counted any good news,” said Mr Isherwood....
International Edition